.Johnson & Johnson’s deprioritization of its transmittable disease pipeline has actually claimed yet another prey such as its dengue infection vaccine mosnodenvir.Mosnodenvir is made to block out interactions between 2 dengue infection healthy proteins. The vaccination endured J&J’s choice in 2013 to merge its own infectious health condition and also vaccine functions, which saw the similarity a late-stage respiratory system syncytial virus program fell coming from the Large Pharma’s pipe and also an E. coli vaccine sold to Sanofi.Mosnodenvir has had a rough time in the medical clinic, along with J&J terminating one hearing due to the impact of COVID-19 on enrollment and also pausing recruitment in another study in 2022.
Yet the support to mosnodenvir showed up to pay in Oct 2023, when the vaccine was revealed to induce a dose-dependent antiviral result on the detectability and beginning of dengue virus serotype 3 in a phase 2 test. That records decline doesn’t seem to have actually been enough to save mosnodenvir for long, along with the Big Pharma declaring this morning that it is actually terminating a follow-up phase 2 industry research. The decision is connected to a “critical reprioritization of the business’s transmittable ailments R&D collection,” added J&J, which stressed that no safety problems had actually been actually determined.” Johnson & Johnson will certainly continue to sustain the fight versus dengue through discussing study results with the clinical area later on,” the pharma said in the launch.J&J had been actually purchasing dengue for over a many years, including releasing a Satellite Center for Global Health And Wellness Finding at the Duke-NUS Medical School in Singapore in 2022.
The facility has actually been actually concentrated on speeding up early-stage discovery analysis to “deal with the increasing challenge of flaviviruses” including dengue as well as Zika.